Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alzamend Neuro, Inc.ALZN · Entity 8081 | Director | October 23, 2025 | October 24, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alzamend Neuro, Inc.
Report date October 23, 2025 · Filed October 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25 |
Reported balance
After 2025-10-23 transaction · row 1
1 source rowRow 1 · 2025-10-23 · Sale · Disposed 30 · Balance 25 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 23, 2025 Filed Oct 24, 2025 16:30 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | SaleCommon Stock | 30 | $2.29 | $68.70 |
DisclosureSEC source: 0001214659-25-015288 · marketforms-71141.xml · nonDerivative · entry 1 McGrath Lynne Fahey · CIK 0001866270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25 Read SEC document |
| December 26, 2023 Filed May 16, 2024 16:30 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | SaleCommon Stock | 666 | $0.88 | $586.75 |
DisclosureSEC source: 0001214659-24-009438 · marketforms-65906.xml · nonDerivative · entry 1 McGrath Lynne Fahey · CIK 0001866270 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · ownership.nature: The shares were sold in an individual retirement account owned by Mrs. McGrath's spouse. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 16:30 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | PurchaseCommon Stock | 10,000 | $0.44 | $4,350.00 |
DisclosureSEC source: 0001214659-23-004146 · marketforms-61011.xml · nonDerivative · entry 1 McGrath Lynne Fahey · CIK 0001866270 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 10,000 F1 · ownership.nature: The shares were purchased in an individual retirement account owned by Mrs. McGrath's spouse. Mrs. McGrath disclaims beneficial ownership of the shares held by her spouse, and the inclusion of these shares shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 28, 2022 Filed Apr 6, 2022 19:47 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | SaleCommon Stock | 25,000 | $1.21 | $30,325.00 |
DisclosureSEC source: 0001214659-22-004914 · marketforms-55974.xml · nonDerivative · entry 1 McGrath Lynne Fahey · CIK 0001866270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 F1 · price: The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average purchase price of $1.213. The range of sale prices on the transaction date was $1.19 to $1.23 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. Read SEC document |
| March 28, 2022 Filed Apr 8, 2022 17:00 UTC Amendment | Alzamend Neuro, Inc. ALZN · Entity 8081 | SaleCommon Stock | 25,000 | $1.21 | $30,325.00 |
DisclosureSEC source: 0001214659-22-004992 · marketforms-55978.xml · nonDerivative · entry 1 McGrath Lynne Fahey · CIK 0001866270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 F2 · price: The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average purchase price of $1.213. The range of sale prices on the transaction date was $1.19 to $1.23 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F1 · acquired: The original Form 4 filed on April 6, 2022, is amended by this Form 4 amendment to correct a typographical error in Table I Column 4 from "A" to "D". Read SEC document |
| March 15, 2022 Filed Mar 15, 2022 19:09 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | Exercise / conversionRestricted Stock Grant · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-003986 · marketforms-55802.xml · derivative · entry 2 McGrath Lynne Fahey · CIK 0001866270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2022-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Common Stock, par value $0.0001, of Alzamend Neuro, Inc. F3 · derivative.exercise_date: 2,778 and 47,222 restricted shares previously vested on September 13, 2021 and October 13, 2021, respectively, with the final 50,000 shares of restricted stock vesting on March 15, 2022. Read SEC document |
| March 15, 2022 Filed Mar 15, 2022 19:09 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | Exercise / conversionCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-003986 · marketforms-55802.xml · nonDerivative · entry 1 McGrath Lynne Fahey · CIK 0001866270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the vesting of restricted stock. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 17:00 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | Exercise / conversionRestricted Stock Grant · Derivative | 47,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-010561 · marketforms-54024.xml · derivative · entry 2 McGrath Lynne Fahey · CIK 0001866270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 47,222 shares Expires 2022-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Common Stock, par value $0.0001, of Alzamend Neuro, Inc. F3 · derivative.exercise_date: The restricted stock grant was amended on October 13, 2021, such that 47,222 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock shall vest on March 15, 2022. 2,778 shares previously vested on September 13, 2021. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 17:00 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | Exercise / conversionCommon Stock | 47,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-010561 · marketforms-54024.xml · nonDerivative · entry 1 McGrath Lynne Fahey · CIK 0001866270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the vesting of restricted stock. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 17:01 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | Exercise / conversionRestricted Stock Grant · Derivative | 2,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-009540 · marketforms-53816.xml · derivative · entry 2 McGrath Lynne Fahey · CIK 0001866270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,222 Underlying: Common Stock · 2,778 shares Expires 2024-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Common Stock, par value $0.0001, of Alzamend Neuro, Inc. F3 · derivative.exercise_date: The restricted stock grant vests in 36 equal monthly installments commencing on September 13, 2021. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 17:01 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | Exercise / conversionCommon Stock | 2,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-009540 · marketforms-53816.xml · nonDerivative · entry 1 McGrath Lynne Fahey · CIK 0001866270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the vesting of restricted stock. Read SEC document |
| June 15, 2021 Filed Jul 16, 2021 17:01 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | GrantStock Options (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001214659-21-007597 · marketforms-53420.xml · derivative · entry 2 McGrath Lynne Fahey · CIK 0001866270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2026-09-12 F3 · derivative.exercise_date: The stock options (the "Options") vest in 36 equal monthly installments commencing on September 13, 2021 and are exercisable upon vesting. Read SEC document |
| June 15, 2021 Filed Jul 16, 2021 17:01 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | GrantRestricted Stock Grant · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-007597 · marketforms-53420.xml · derivative · entry 1 McGrath Lynne Fahey · CIK 0001866270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2024-09-13 F1 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Common Stock, par value $0.0001, of Alzamend Neuro, Inc. F2 · derivative.exercise_date: The restricted stock grant vest contemporaneously with the Options (as defined below). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.